RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..2 of 2 - per page
Order by
Esmolol 100mg/10ml vial
Ultrashort acting beta blocker Esmolol for use in anesthesia, intensive care, cardiology and internal medicine. More
Esmolol 2500 mg/10ml ampoule
Ultrashort acting beta blocker Esmolol for use in anesthesia, intensive care, cardiology and internal medicine. More
Displaying 1..2 of 2 - per page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Failure of TAK442 to Meet the Primary End-point in a Phase II Study Underlines the Challenging Clinical Development Environment for Anticoagulants in Acute Coronary Syndromes
Nov 2010 - 5 pages - $500
Acute Coronary Syndromes Therapy Area Pipeline Report
Nov 2010 - 329 pages - $1,495
Epidemiology: Acute Coronary Syndrome - Now affecting primarily the oldest populations
Jul 2011 - 46 pages - $3,800
Myocardial Infarction Therapy Area Pipeline Report
Nov 2010 - 289 pages - $1,495
Acute Coronary Syndromes - Pipeline Review, Q1 2011
Feb 2011 - 62 pages - $500
Post-Myocardial Infarction - Pipeline Review, Q2 2011
May 2011 - 29 pages - $500
Myocardial Infarction - Pipeline Review, Q1 2011
Jan 2011 - 83 pages - $500
Myocardial Infarction - Pipeline Review, Q3 2011
Jul 2011 - 76 pages - $500
Epidemiology: Hypertension – Rising with increasing obesity and population growth
Oct 2011 - 44 pages - $5,700
Myocardial Infarction Global Clinical Trials Review, Q4, 2010
Dec 2010 - 78 pages - $1,000
More Related Market Research Reports >>>

Your selection

Industry sector
Biotechnology del
Therapeutic target
Cardiovascular del
Acute coronary syndromes del
Myocardial infarction del
Development phase
Phase III del

Browse By

Industry sector
Assay systems
Diagnostic test systems
Gene therapy
Human diagnostics
Human therapeutics
Nanotechnology
Other
Research supplies
Stem cells

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us